Concurrent immunotherapy is associated with increased radiation necrosis risk in lung cancer patients with brain metastases treated with stereotactic radiosurgery [0.03%]
立体放射外科治疗伴脑转移的肺癌患者同时接受免疫治疗与较高的放射性坏死风险相关
Guochang Du,Wanjing Li,Ji Li et al.
Guochang Du et al.
Purpose: The aim of this study was to evaluate the factors associated with local control and radiation necrosis (RN) after stereotactic radiosurgery (SRS) in patients with brain metastases from lung cancer. ...
Systemic immune-inflammation index may be used to predict the development of colorectal cancer from colonic polyps [0.03%]
系统免疫炎症指数可能用于预测结肠息肉向结直肠癌的发展风险
Ying Chun,Jing Xia,Chaosheng Peng
Ying Chun
Aims: This study aims to assess whether the Systemic Immune-Inflammation Index (SII) can serve as a predictive biomarker for the progression of colonic polyps to colorectal cancer (CRC). ...
Real-world treatment patterns and medical burden in patients with NSCLC: a retrospective database study in Japan [0.03%]
日本非小细胞肺癌患者的实际治疗模式和医疗负担：一项回顾性数据库研究
Linghua Xu,Sona-Sanae Aoyagi,Yusuke Nukui et al.
Linghua Xu et al.
Aim: We investigated treatment patterns and healthcare resource utilization (HRU) to clarify unmet medical needs in second and later lines among Japanese patients with advanced non-small cell lung cancer (NSCLC). ...
Significance of the HALP score in patients with primary liver cancer undergoing hepatectomy: a meta-analysis [0.03%]
HALP评分在原发性肝癌患者肝脏切除术中意义的Meta分析
Min Zhang,Kailin Xu,Jufeng Ye
Min Zhang
Aim: This meta-analysis systematically assesses assessment of the association between the preoperative Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score and the prognosis in patients with primary liver cancer und...
Zolbetuximab for gastroesophageal adenocarcinoma: drug review and lessons from the frontlines [0.03%]
胃食管腺癌的Zolbetuximab：药物综述及前线用药经验教训
Jane E Rogers,Wendy M Covert,Michael Leung et al.
Jane E Rogers et al.
Molecular distinctions have started to define treatment decisions in advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJAC), malignancies in need of improved outcomes. Claudin 18.2 (CLDN18.2) represents a...
The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial [0.03%]
整合的31基因表达谱检测可识别出可以省略哨点淋巴结活检程序的皮肤黑色素瘤低危患者：一项前瞻性多中心试验的结果
Timothy Beard,J Michael Guenther,Stanley P Leong et al.
Timothy Beard et al.
Aims: Prospectively confirm use of the integrated 31-gene expression profile test (i31-SLNB) in patients with cutaneous melanoma to predict sentinel lymph node biopsy (SLNB) positivity and assess recurrence rates in those...
The broad societal value of pembrolizumab for women's cancer in Canada [0.03%]
帕博利珠单抗在加拿大女性癌症中的广泛社会价值
Elizabeth Brook,Karl Patterson,Nishini Wijenayake et al.
Elizabeth Brook et al.
Aims: The impact of women's cancers is multifaceted, with broad societal and economic consequences. Health technology assessments often rely solely on costs and outcomes directly relevant to the healthcare system. Our stu...
ToPCourT protocol: a phase II trial of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced/unresectable or metastatic triple-negative breast cancer [0.03%]
ToPCourT方案Ⅱ期临床研究：德鲁替康联合派姆单抗、吉西他滨和卡铂治疗局部晚期/不可切除或转移性三阴乳腺癌的一项Ⅱ期临床研究
Megan B Sears-Smith,Ashley Matusz-Fisher,James T Symanowski et al.
Megan B Sears-Smith et al.
Triple-negative breast cancer (TNBC) is a clinically aggressive and difficult to treat malignancy. It has a poorer prognosis when compared to the hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-positi...
Systematic review of reflex biomarker testing and its influence on diagnostic and treatment timelines in cancer pathways [0.03%]
系统审查反射生物标志物检测及其对癌症途径诊断和治疗时间表的影响
Christopher Felix Brewer,Edward Donnely
Christopher Felix Brewer
Background: Reflex biomarker testing, where molecular assays are automatically requested at diagnosis, has been proposed to accelerate cancer care. However, its operational and clinical impact across tumor types has not b...
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib [0.03%]
POIESIS研究：鲁索利替尼治疗反应不佳的jak抑制剂初治骨髓纤维化患者的添加navtemadlin疗法三期临床试验
Pankit Vachhani,Abdulraheem Yacoub,Raajit Rampal et al.
Pankit Vachhani et al.
Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and instead experience suboptimal reductions in sp...